Cellceutix Plans for Future Trials Aimed at the Latest

New Post Public Reply Private Reply Replies (3) Message Board
Dynabolic
Cellceutix Plans for Future Trials Aimed at the Latest Initiatives of ‘Breakthrough’ Designation by the Food and Drug Administration

Cellceutix Conducts Research on Retinoblastoma Cancer

Beverly, MA - Cellceutix Corporation (OTCBB: CTIX) (the

"Company"), a clinical stage biopharmaceutical company

focused on discovering small molecule drugs to treat unmet

medical conditions, including drug-resistant cancers and

autoimmune diseases, is pleased to report that Kevetrin™,

the Company’s lead anti-cancer compound currently in a

Phase 1 clinical trial at Harvard Cancer Center for solid

tumors, has shown to be effective against animal models of

retinoblastoma.

Retinoblastoma is a rare and serious disease in which

cancer cells grow in the retina of the eye. According to the

American Cancer Society, less than 300 children are

diagnosed with retinoblastoma each year in the United

States. It is the most common type of eye cancer in children

and accounts for 6 percent of all cancers in children under

the age of five. It is most frequently diagnosed in infants

and very young children; the average age of children when

they are diagnosed is 2. (www.cancer.org/cancer/

retinoblastoma)

Current therapies are difficult to tolerate especially in

children, e.g., removal of the eye, intense radiation therapy,

or chemotherapy given either systemically or locally in the

eye, and are limited in their effectiveness. The need for an

effective therapy against retinoblastoma is urgently

needed.

The Company conducted pre-clinical studies using human

retinoblastoma cells (WERI-Rb-1) in nude mice that were

implanted either subcutaneously or directly into the eye,

intravitreally. Treatment with Kevetrin significantly

reduced the tumor volume by more than half in the

subcutaneous tumor model and showed a significant

improvement in the clarity of the eye in mice treated with

Kevetrin as shown in the photographs below and on our

website at www.cellceutix.com/kevetrin.

Given the limited treatment options, devastating effects,

and small patient population, Cellceutix believes that

retinoblastoma would make an excellent candidate for a

phase 2/3 trial once our present phase 1 trial is completed. It

would qualify for a number of FDA programs (Orphan, Fast

Track and Breakthrough) that can exponentially shrink

development time, should clinical data support the current

research.

“While our Phase 1 clinical trial is ongoing, we are planning

for future trials that are aimed directly at the latest

initiatives of the Food and Drug Administration to expedite

development of ‘breakthrough’ technologies to

commercialization,” commented Dr. Krishna Menon, Chief

Scientific Officer at Cellceutix. “The data from the studies

affirm that Kevetrin may be useful in a new tumor type, in

addition to the other indications that we are studying.

Kevetrin has delivered robust results against all indications

tested to date. Cellceutix’s strategy is to have multiple trials

ongoing against multiple cancer types concurrently. We are

conducting testing against several more cancers to

delineate the quickest path to market to build corporate

and shareholder value.”

About Kevetrin™

As a completely new class of chemistry in medicine,

Kevetrin™ has significant potential to be a major

breakthrough in the treatment of solid tumors. Mechanism

of action studies showed Kevetrin's unique ability to affect

both wild and mutant types of p53 (often referred to as the

"Guardian Angel Gene" or the "Guardian Angel of the

Human Genome") and that Kevetrin strongly induced

apoptosis (cell death), characterized by activation of

Caspase 3 and cleavage of PARP. Activation of p53 also

induced apoptosis by inducing the expression of p53 target

gene PUMA. p53 is an important tumor suppressor that acts

to restrict proliferation by inducing cell cycle checkpoints,

apoptosis, or cellular senescence.

In more than 50 percent of all human carcinomas, p53 is

limited in its anti-tumor activities by mutations in the

protein itself. Currently, there are greater than 10 million

people with tumors that contain inactivated p53, while a

similar number have tumors in which the p53 pathway is

partially abrogated by inactivation of other signaling

components. This has left cancer researchers with the

grand challenge of searching for therapies that could

restore the protein's protective function, which Kevetrin

appears to be doing the majority of the time.

Further information on the clinical trial, titled "A Phase 1,

Open-Label, Dose-Escalation, Safety, Pharmacokinetic and

Pharmacodynamic Study of Kevetrin

(Thioureidobutyronitrile) Administered Intravenously, in

Patients With Advanced Solid Tumors," is available at: http:/

/clinicaltrials.gov/ct2/show/NCT01664000?term=

cellceutix&rank=1

About Cellceutix

Headquartered in Beverly, Massachusetts, Cellceutix is a

publicly traded company under the symbol "CTIX". It is an

emerging bio-pharmaceutical company focused on the

development of its pipeline of compounds targeting areas of

unmet medical need. Our flagship compound, Kevetrin™, is

an anti-cancer drug which has demonstrated the ability in

pre-clinical studies to regulate the p53 pathway and attack

cancers which have proven resistant to today's cancer

therapies (drug-resistant cancers). Cellceutix also owns the

rights to seven other drug compounds, including KM-133,

which is in development for psoriasis, and KM-391 for the

treatment of the core symptoms of autism. More

information is available on the Cellceutix web site at

www.cellceutix.com.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not

strictly historical, including statements as to revenue

projections, business strategy, outlook, objectives, future

milestones, plans, intentions, goals, future financial

conditions, future collaboration agreements, the success of

the Company's development, events conditioned on

stockholder or other approval, or otherwise as to future

events, such statements are forward-looking, and are made

pursuant to the safe harbor provisions of the Private

Securities Litigation Reform Act of 1995. The forward-

looking statements contained in this release are subject to

certain risks and uncertainties that could cause actual

results to differ materially from the statements made.

Factors that may impact Cellceutix's success are more fully

disclosed in Cellceutix's most recent public filings with the

U.S. Securities and Exchange Commission.

Copyright © 2013 Cellceutix Corporation, All rights reserved. You requested to receive email alerts about Cellceutix at our website www.cellceutix.com Our mailing address is: Cellceutix Corporation 100 Cumming Center, Suite 151-B Beverly, MA 01915

Add us to your address book

unsubscribe from this list | update subscription preferences

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Avenir Nears 19.99% Grid Stake After Falcon West Resource

Updated Category News Views 76

Falcon West finally put enough geological meat on the bone to make Avenir reach for its wallet. Avenir Minerals expects to buy 29,388,127 Grid Metals common shares on or about November 30, 2026, taking its non-diluted position to 19.99%. That number is not accidental. It is the usual Canadian strategic-investor ceiling before the conversation starts getting considerably...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 40

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 161

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 79

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading
Surf City Seasons Put Vacation Rental Timing in Focus

Updated Category News Views 42

Summer’s Calendar Does the Talking School bells, not seagulls, appear to set the pace for Surf City’s rental market. Chris Rackley’s seasonal guide makes a pretty grounded point: the “best” time to visit Surf City, North Carolina, is not some universal magic week on a postcard. It depends on whether a traveler needs peak beach weather, wants elbow room, or...

Continue Reading

Top 5 Most Recently Viewed Articles

FHLBank San Francisco's $10M Investment in Housing Solutions

Updated Category News Views 188

FHLBank San Francisco's Strategic Commitment to Affordable Housing In a significant move to address housing affordability, the Federal Home Loan Bank of San Francisco (FHLBank San Francisco) has made a $10 million investment in a bond issuance backed by Freddie Mac. This vital investment is set to maintain the affordability of 436 housing units aimed at low-income...

Continue Reading
Essential Tips for New Dog Owners: Making Them Feel at Home

Updated Category News Views 232

Essential Tips for Welcoming a New Dog Bringing a new dog into your home can be an exhilarating experience filled with joys and challenges. This is especially true during peak pet adoption seasons like December and January when many families choose to add a furry member to their household. As a pet owner, providing a nurturing and stable environment is essential for your...

Continue Reading
Understanding New Fortress Energy's Recent Share Surge

Updated Category News Views 377

New Fortress Energy Celebrates Share Price Increase Recently, shares of New Fortress Energy Inc. (NASDAQ: NFE) experienced a remarkable after-hours jump of 20.54%, bringing the price up to $1.76. This impressive rise follows a strong performance during the regular trading session, where the stock concluded up 25.86% at $1.46. Details of the Credit Facility Amendment A...

Continue Reading
Koi Computers Celebrates Renewal of ISO 9001 Certification

Updated Category News Views 167

Koi Computers Celebrates ISO 9001:2015 Certification Renewal Koi Computers, a notable provider of high-performance computing (HPC) solutions to the government sector, has proudly renewed its ISO 9001:2015 certification. This achievement showcases the company’s unwavering commitment to quality management across all aspects of its operations, affirming its dedication to...

Continue Reading
Banijay Group's Recent Share Transactions Summary

Updated Category News Views 311

Overview of Share Transactions Banijay Group N.V. announced recent transactions concerning its shares as part of a broader strategy aligned with investor interests. These transactions occurred within the timeframe of early December and reflect ongoing activity in the company's stock management. Detailed Breakdown of Transactions From December 2 to December 6, Banijay...

Continue Reading